Intimal thickening after vascular injury may be modulated in part by heparin binding growth factors. We hypothesized that placement of a therapeutic polymer in the periadventitial space capable of tightly binding growth factors might alter the vascular response to injury. We first demonstrated that incubation of rat aortic smooth muscle cells with an insoluble, sulfated polymer of beta-cyclodextrin (P-CDS) was associated with a dose-dependent inhibition of proliferation induced by fetal calf serum, fibroblast growth factor-2 (FGF-2), platelet-derived growth factor BB, or epidermal growth factor. Preincubation studies of P-CDS with FGF-2 revealed a very rapid removal of mitogenic activity. Using radiolabeled FGF-2 (0.25 microg/ml), we observed a very rapid association rate (0.34 +/- 0.07 min-1, n=4) and a very slow dissociation rate (3.3 +/- 0.2 X 10(-7) min-1) at 37 degrees C, suggesting a high affinity interaction. Using both Transwell and linear under-agarose assays, we demonstrated a significant inhibition of random migration (chemokinesis) by P-CDS. Unsulfated polymeric beta-cyclodextrin (P-CD) had little if any of these effects, suggesting that the high negative charge density of P-CDS was important for the effects. Finally, rats undergoing carotid artery balloon injury were randomized to treatment with periadventitial P-CDS or no treatment, and were killed at 4 (n=20), 14 (n=59), and 88 d (n=14). Morphometric analysis demonstrated significant and sustained inhibition of intimal thickening in P-CDS-treated rats at 14 (P < 0.01) and 88 d (P < 0.05) using absolute intimal area or intima/media area ratios. No inhibition was seen in a group of rats treated with P-CD. In P-CDS-treated rats, bromodeoxyuridine labeling studies revealed fewer labeled smooth muscle cells in the intima at 14 d (P=0.01), while staining with Evans blue revealed enhanced late endothelial cell regrowth. Thus, periadventitially applied sulfated beta-cyclodextrin polymer, which can tightly bind heparin binding growth factors, inhibits intimal thickening in vivo in a sustained fashion without using an additional delivery system. These studies suggest that cellular processes mediated by heparin binding growth factors may be modulated by P-CDS.
W B Bachinsky, E S Barnathan, H Liu, S S Okada, A Kuo, P N Raghunath, M Muttreja, R J Caron, J E Tomaszewski, M A Golden
Title and authors | Publication | Year |
---|---|---|
A multifunctional surface for blood contact with fibrinolytic activity, ability to promote endothelial cell adhesion and inhibit smooth muscle cell adhesion
H Gu, X Chen, Q Yu, X Liu, W Zhan, H Chen, JL Brash |
Journal of Materials Chemistry B | 2017 |
The antiangiogenic properties of sulfated β-cyclodextrins in anticancer formulations incorporating 5-fluorouracil:
CA Watson, KL Vine, JM Locke, A Bezos, CR Parish, M Ranson |
Anti-Cancer Drugs | 2013 |
In vivo quantitative assessment of catheter patency in rats
J Yang, JM Maarek, DP Holschneider |
Laboratory Animals | 2005 |
Separate and Combined Effects of Local and Continuous Intravenous Administration of β-Cyclodextrin Tetradecasulfate on Intimal Hyperplasia after Angioplasty in Porcine Coronary Arteries
NF Meneveau, BD Klugherz, B Chaquor, MA Golden, MM Jouille, E Macarek, PB Weisz, RL Wilensky |
Journal of cardiovascular pharmacology and therapeutics | 2003 |
Beta-cyclodextrin tetradecasulfate, a novel cyclic oligosaccharide, inhibits thrombus and neointimal formation after coronary vascular injury
NF Meneveau, BD Klugherz, B Chaqour, V Anand, JE Tomaszewski, MM Joullié, E Macarak, M Golden, PB Weisz, RL Wilensky |
Coronary Artery Disease | 2002 |
Adenoviral Mediated Uteroglobin Gene Transfer to the Adventitia Reduces Arterial Intimal Hyperplasia
JV Lombardi, M Naji, RA Larson, SV Ryan, A Naji, B Koeberlein, MA Golden |
Journal of Surgical Research | 2001 |
Targeting endogenous platelet-derived growth factor B-chain by adenovirus-mediated gene transfer potently inhibits in vivo smooth muscle proliferation after arterial injury
J Deguchi, T Namba, H Hamada, T Nakaoka, J Abe, O Sato, T Miyata, M Makuuchi, K Kurokawa, Y Takuwa |
Gene Therapy | 1999 |
Proceedings of the Ninth International Symposium on Cyclodextrins
JJ Labandeira, JL Vila-Jato |
1999 | |
Medical therapies for the prevention of restenosis after percutaneous coronary interventions
WH Frishman, R Chiu, BR Landzberg, M Weiss |
Current Problems in Cardiology | 1998 |
Cyclodextrin Drug Carrier Systems
K Uekama, F Hirayama, T Irie |
Chemical Reviews | 1998 |
Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation
T Irie, K Uekama |
Journal of Pharmaceutical Sciences | 1997 |
A basic compositional requirement of agents having heparin-like cell-modulating activities
PB Weisz, MM Joullié, CM Hunter, KM Kumor, Z Zhang, E Levine, E Macarak, D Weiner, ES Barnathan |
Biochemical Pharmacology | 1997 |
Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides
W Wang, HJ Chen, A Schwartz, PJ Cannon, CA Stein, LE Rabbani |
Journal of Clinical Investigation | 1996 |
Inhibition of vein graft intimal and medial thickening by periadventitial application of a sulfated carbohydrate polymer
GJ Toes, ES Barnathan, H Liu, PN Raghunath, JE Tomaszewski, RJ Caron, PB Weisz, W Oeveren, MA Golden |
Journal of Vascular Surgery | 1996 |
Intimal Hyperplasia: Prospects for Its Control in the Human
MA Golden |
Vascular and endovascular surgery | 1996 |